Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Financial News

Angina gene therapy company XyloCor raises $17M series A round

Alicia Parker
December 7, 2018 7:14 PM UTC

Gene therapy company XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million Dec. 6 in a series A round led by Sofinnova Ventures and Life Science Partners.

XyloCor’s lead candidate is XC001, a gene therapy that stimulates the formation of new coronary blood vessels by delivering VEGF in a single myocardial injection. The company plans to start a Phase I trial of XC001 next year to treat refractory angina...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Xylocor Therapeutics Inc.